Interleukin 22 derived from locally activated γδT cells promotes self-renewal and hyperplasia of BC within alveolar epithelium that ultimately assumes serous cell fates in previously injured regions during resolution of the PR8-elicited inflammatory response. This evidence concerns the gene IL22 and breast cancer.